LYMPHOMAS

Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.

Phase 2 data show an outpatient fixed-duration combo yields 79% complete responses and 18.6-month PFS in relapsed mantle cell lymphoma.

Phase 2 data show atezolizumab delivers durable responses in relapsed/refractory NK/T-cell lymphoma, with PD‑L1 markers helping predict benefit.

Registry data show bulky lymphoma drives different treatment choices and mixed survival effects, highlighting the need to standardize tumor bulk definitions.

Liso-cel CAR T plus ibrutinib delivers deep remissions and high uMRD in relapsed CLL/SLL after multiple therapies, with manageable safety.

Explore how REMS removal streamlines CAR T-cell access in second-line DLBCL, plus smart bridging options and who qualifies when relapse strikes fast.

FDA grants designations to off-the-shelf CD19 CAR T cema-cel for MRD+ LBCL consolidation, as ALPHA3 data show strong MRD clearance with outpatient care.

Adding emavusertib to ibrutinib boosts response rates in relapsed/refractory PCNSL, including in BTKi-experienced patients, while safety monitoring addresses prior FDA hold concerns.

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.

Phase 1/2 SIDNEY interim results show EO2463 boosts CD8 T cells, linking to longer PFS and responses in watch-and-wait patients with indolent NHL.

Ten-year RELEVANCE results show chemo-free R2 matches immunochemotherapy for advanced follicular lymphoma, with comparable survival and safety.

Early trial shows off-the-shelf immunotherapy combo boosts responses in relapsed B-cell lymphoma with manageable CRS and safety.

Survey reveals race and sex gaps in lymphoma trial barriers—travel, costs, complexity, and mistrust—pointing to navigators, decentralized visits, and reimbursement fixes.

Phase 3 MANGROVE shows chemo-free zanubrutinib plus rituximab extends PFS in untreated mantle cell lymphoma, with no new safety issues.

Phase 3 trial shows chemo-free epcoritamab plus lenalidomide cuts progression risk in relapsed DLBCL, with no new safety signals.

FDA reviews chemo-free mosunetuzumab plus polatuzumab for relapsed/refractory LBCL, promising outpatient second-line care and longer PFS.

EPCORE FL-1 data showed a consistent benefit with epcoritamab-based treatment in follicular lymphoma.

Off-the-shelf CD19 CAR T azer-cel earns FDA Fast Track after early trials show striking responses in refractory CLL/SLL and marginal zone lymphoma.

LOTIS-5 finds loncastuximab tesirine plus rituximab improves PFS and response rates in relapsed/refractory DLBCL vs R-GemOx.

FDA grants orphan drug status to EO2463 vaccine for watch-and-wait indolent NHL, advancing a potential treatment option and spotlighting promising SIDNEY trial data.

Sonrotoclax gains FDA approval as a promising treatment for relapsed mantle cell lymphoma, showcasing strong efficacy and safety in clinical trials.

Blood MRD reveals hidden DLBCL after chemo; ALPHA3 trials off-the-shelf CD19 CAR T, boosting MRD clearance with low toxicity.

During a live event, Paolo Strati, MD and participants explore when to use CAR T in relapsed LBCL, how bispecific antibodies fit, and practical scan, access, and frontline CD19 strategy shifts.

Final PRIMO phase 2 data show oral duvelisib drives strong responses in relapsed PTCL, standout AITL benefit, with manageable safety signals.

CLOVER-WaM data meet FDA-requested threshold; confirmatory trial planned for fourth quarter 2026.